Management of immunotherapy colitis: Special considerations in the COVID-19 era.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32797685.
- Also identified by DOI 10.1002/cncr.33125 and PMC identifier 7461305.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The evaluation and management of patients with cancer with suspected immune checkpoint inhibitor (ICI) colitis have distinct challenges within the setting of the coronavirus disease 2019 (COVID‐19) pandemic. The approach to the treatment of patients with ICI colitis requires consideration of the risks and benefits of individual immunosuppressive medications and varies based on the presence of a concurrent COVID‐19 infection.
Medical subject headings
- COVID-19
- Colitis
- Immunotherapy
- COVID-19 Drug Treatment